TY - JOUR
T1 - Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy
AU - Sainz-Esteban, Aurora
AU - Prasad, Vikas
AU - Schuchardt, Christiane
AU - Zachert, Carolin
AU - Carril, José Manuel
AU - Baum, Richard P.
PY - 2012/3
Y1 - 2012/3
N2 - Purpose: The aim of the study was to compare sequential 177Lu-DOTA-TATE planar scans ( 177Lu-DOTA-TATE) in patients with metastasized neuroendocrine tumours (NET) acquired during peptide receptor radionuclide therapy (PRRT) for dosimetry purposes with the pre-therapeutic 68Ga-DOTA-TATE positron emission tomography (PET)/CT ( 68Ga-DOTA-TATE) maximum intensity projection (MIP) images obtained in the same patients concerning the sensitivity of the different methods. Methods: A total of 44 patients (59±11 years old) with biopsy-proven NET underwent 68Ga-DOTA-TATE and 177Lu-DOTA-TATE imaging within 7.9±7.5 days between the two examinations. 177Lu-DOTA- TATE planar images were acquired at 0.5, 2, 24, 48 and 72 h post-injection; lesions were given a score from 0 to 4 depending on the uptake of the radiopharmaceutical (0 being lowest and 4 highest). The number of tumour lesions which were identified on 177Lu-DOTA-TATE scans (in relation to the acquisition time after injection of the therapeutic dose as well as with regard to the body region) was compared to those detected on 68Ga-DOTA-TATE studies obtained before PRRT. Results: A total of 318 lesions were detected; 280 (88%) lesions were concordant. Among the discordant lesions, 29 were 68Ga-DOTA-TATE positive and 177Lu-DOTA-TATE negative, whereas 9 were 68Ga-DOTA-TATE negative and 177Lu-DOTA-TATE positive. The sensitivity, positive predictive value and accuracy for 177Lu-DOTA-TATE as compared to 68Ga-DOTA-TATE were 91, 97 and 88%, respectively. Significantly more lesions were seen on the delayed (72 h) 177Lu-DOTA-TATE images (91%) as compared to the immediate (30 min) images (68%). The highest concordance was observed for bone metastases (97%) and the lowest for head/neck lesions (75%). Concordant lesions (n=77; mean size 3.8 cm) were significantly larger than discordant lesions (n=38; mean size 1.6 cm) (p<0.05). No such significance was found for differences in maximum standardized uptake value (SUV max). However, concordant liver lesions with a score from 1 to 3 in the 72-h 177Lu-DOTA-TATE scan had a lower SUV max (n=23; mean 10.9) than those metastases with a score of 4 (n=97; mean SUV max 18) (p<0.05). Conclusion: Although 177Lu-DOTA-TATE planar dosimetry scans exhibited a very good sensitivity for thedetection of metastases, they failed to pick up 9% of lesions seen on the 68Ga-DOTA-TATE PET/CT. Three-dimensional dosimetry using single photon emission computed tomography/CT could be applied to investigate this issue further. Delayed (72 h) images are most suitable for drawing regions of interest for dosimetric calculations.
AB - Purpose: The aim of the study was to compare sequential 177Lu-DOTA-TATE planar scans ( 177Lu-DOTA-TATE) in patients with metastasized neuroendocrine tumours (NET) acquired during peptide receptor radionuclide therapy (PRRT) for dosimetry purposes with the pre-therapeutic 68Ga-DOTA-TATE positron emission tomography (PET)/CT ( 68Ga-DOTA-TATE) maximum intensity projection (MIP) images obtained in the same patients concerning the sensitivity of the different methods. Methods: A total of 44 patients (59±11 years old) with biopsy-proven NET underwent 68Ga-DOTA-TATE and 177Lu-DOTA-TATE imaging within 7.9±7.5 days between the two examinations. 177Lu-DOTA- TATE planar images were acquired at 0.5, 2, 24, 48 and 72 h post-injection; lesions were given a score from 0 to 4 depending on the uptake of the radiopharmaceutical (0 being lowest and 4 highest). The number of tumour lesions which were identified on 177Lu-DOTA-TATE scans (in relation to the acquisition time after injection of the therapeutic dose as well as with regard to the body region) was compared to those detected on 68Ga-DOTA-TATE studies obtained before PRRT. Results: A total of 318 lesions were detected; 280 (88%) lesions were concordant. Among the discordant lesions, 29 were 68Ga-DOTA-TATE positive and 177Lu-DOTA-TATE negative, whereas 9 were 68Ga-DOTA-TATE negative and 177Lu-DOTA-TATE positive. The sensitivity, positive predictive value and accuracy for 177Lu-DOTA-TATE as compared to 68Ga-DOTA-TATE were 91, 97 and 88%, respectively. Significantly more lesions were seen on the delayed (72 h) 177Lu-DOTA-TATE images (91%) as compared to the immediate (30 min) images (68%). The highest concordance was observed for bone metastases (97%) and the lowest for head/neck lesions (75%). Concordant lesions (n=77; mean size 3.8 cm) were significantly larger than discordant lesions (n=38; mean size 1.6 cm) (p<0.05). No such significance was found for differences in maximum standardized uptake value (SUV max). However, concordant liver lesions with a score from 1 to 3 in the 72-h 177Lu-DOTA-TATE scan had a lower SUV max (n=23; mean 10.9) than those metastases with a score of 4 (n=97; mean SUV max 18) (p<0.05). Conclusion: Although 177Lu-DOTA-TATE planar dosimetry scans exhibited a very good sensitivity for thedetection of metastases, they failed to pick up 9% of lesions seen on the 68Ga-DOTA-TATE PET/CT. Three-dimensional dosimetry using single photon emission computed tomography/CT could be applied to investigate this issue further. Delayed (72 h) images are most suitable for drawing regions of interest for dosimetric calculations.
KW - Dosimetry scan
KW - Ga-DOTA-TATE
KW - Lu-DOTA-TATE
KW - Neuroendocrine tumour
UR - http://www.scopus.com/inward/record.url?scp=84859647808&partnerID=8YFLogxK
U2 - 10.1007/s00259-011-2003-x
DO - 10.1007/s00259-011-2003-x
M3 - Article
C2 - 22183108
AN - SCOPUS:84859647808
SN - 1619-7070
VL - 39
SP - 501
EP - 511
JO - European Journal of Nuclear Medicine and Molecular Imaging
JF - European Journal of Nuclear Medicine and Molecular Imaging
IS - 3
ER -